(IN BRIEF) Basilea Pharmaceutica Ltd has received an additional USD 5.4 million from BARDA to continue development of its novel oral antibiotic ceftibuten-ledaborbactam etzadroxil. The antibiotic is being developed for complicated urinary tract infections, including pyelonephritis, particularly infections caused by … Read the full press release
Posted in Business, Financial, Government, Healthcare, Investment, Pharma & Biotech, Science, Switzerland, Technology
Tagged Additional BARDA Support Brings Basilea Funding for Ceftibuten-Ledaborbactam to USD 30.8 Million, Administration for Strategic Preparedness and Response, Allschwil, anti-infectives, antimicrobial resistance, ASPR, BARDA, BARDA Awards Further Funding to Basilea for Ceftibuten-Ledaborbactam Development, Basilea, Basilea Advances Oral Antibiotic Candidate for Complicated Urinary Tract Infections, Basilea Pharmaceutica, Basilea Pharmaceutica Ltd, beta lactam beta lactamase inhibitor, Biomedical Advanced Research and Development Authority, BL/BLI, boronic acid beta-lactamase inhibitor, BSLN, carbapenemases, ceftibuten, ceftibuten ledaborbactam etzadroxil, ceftibuten-ledaborbactam, cephalosporinases, complicated urinary tract infections, Cresemba®, cUTI, David Veitch, Enterobacterales, ESBL, extended spectrum beta-lactamases, Fast Track Designation, fungal infections, Gram-negative bacteria, investigational drug, KPC, ledaborbactam, ledaborbactam etzadroxil, multidrug resistant bacteria, non-dilutive funding, novel oral antibiotic, oral cephalosporin, OXA-48, pyelonephritis, QIDP designation, Qualified Infectious Disease Product, Severe Bacterial Infections, SIX Swiss Exchange, Switzerland, U.S Department of Health and Human Services, U.S. FDA, USD 172 million contract potential, USD 30.8 million total funding, USD 5.4 million funding, Zevtera®
(IN BRIEF) Basilea Pharmaceutica has received an additional USD 13.3 million from BARDA to continue development of ceftibuten-ledaborbactam etzadroxil, an investigational oral beta-lactam/beta-lactamase inhibitor antibiotic being developed for complicated urinary tract infections, including pyelonephritis. The latest tranche brings BARDA’s total … Read the full press release
Posted in Business, Economy, Financial, Government, Healthcare, Industrial, Management, Marketing, Pharma & Biotech, Science, Switzerland, Technology, Transportation & Logistics
Tagged Administration for Strategic Preparedness and Response, Allschwil, antibiotic resistance, antimicrobial resistance, ASPR, BARDA, BARDA Funding Supports Basilea’s Efforts to Address Unmet Need in Oral Treatment of Complicated Urinary Tract Infections, Basilea, Basilea Pharmaceutica Ltd, Basilea Receives Additional USD 13.3 Million BARDA Funding to Advance Novel Oral Antibiotic Development, Basilea Secures Additional Non-Dilutive Funding to Prepare Ceftibuten-Ledaborbactam for Phase 3 Development, Basilea Secures Additional USD 13.3 Million BARDA Funding to Advance Development of Novel Oral Antibiotic Ceftibuten-Ledaborbactam, beta-lactam, beta-lactamase inhibitor, Biomedical Advanced Research and Development Authority, BL/BLI combination, carbapenemases, ceftibuten, ceftibuten ledaborbactam etzadroxil, ceftibuten-ledaborbactam, cephalosporinases, complicated urinary tract infections, cUTI, David Veitch, Enterobacterales, ESBL, extended spectrum beta-lactamases, Fast Track Designation, Gram-negative bacteria, infectious diseases, KPC, ledaborbactam etzadroxil, MDR Enterobacterales, multidrug resistant bacteria, non-dilutive funding, novel oral antibiotic, OXA-48, phase 3 programme, pyelonephritis, QIDP designation, Qualified Infectious Disease Product, SIX: BSLN, Switzerland, U.S Department of Health and Human Services, U.S. FDA
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?